UNDIFFERENTIATED PLEOMORPHIC SARCOMA
Clinical trials for UNDIFFERENTIATED PLEOMORPHIC SARCOMA explained in plain language.
Never miss a new study
Get alerted when new UNDIFFERENTIATED PLEOMORPHIC SARCOMA trials appear
Sign up with your email to follow new studies for UNDIFFERENTIATED PLEOMORPHIC SARCOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New hope to stop rare bone cancers from returning
Disease control Recruiting nowThis study is testing if taking a drug called regorafenib for up to a year after finishing initial cancer treatment can help keep bone sarcomas from coming back. It will compare patients who take the drug to those who receive standard monitoring with no extra medication. The goal…
Matched conditions: UNDIFFERENTIATED PLEOMORPHIC SARCOMA
Phase: NA • Sponsor: Centre Leon Berard • Aim: Disease control
Last updated Apr 03, 2026 14:41 UTC
-
Targeted attack: new combo therapy fights tough limb cancers
Disease control Recruiting nowThis study is testing whether a new combination treatment can safely slow the growth of advanced sarcoma tumors in an arm or leg. It combines a targeted limb chemotherapy procedure with a drug that helps the immune system fight cancer. The goal is to see if this approach can keep…
Matched conditions: UNDIFFERENTIATED PLEOMORPHIC SARCOMA
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Mar 13, 2026 15:05 UTC
-
New hope for Tough-to-Treat sarcomas: Dual-Attack drug trial
Disease control Recruiting nowThis trial is testing whether combining two existing cancer drugs—pembrolizumab and cabozantinib—can help control advanced sarcomas that have stopped responding to standard treatments. It will enroll about 119 adults with specific types of advanced sarcoma. The main goal is to se…
Matched conditions: UNDIFFERENTIATED PLEOMORPHIC SARCOMA
Phase: PHASE2 • Sponsor: Institut Bergonié • Aim: Disease control
Last updated Mar 10, 2026 12:53 UTC